Compare Abbott Laboratories (ABT) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Tidewater Inc — how do they compare? Abbott Laboratories trades at $110.94 (market cap $187.95B), while Tidewater Inc trades at $92.71 (market cap $4.54B). The key difference: Abbott Laboratories is far larger — about 41.4× Tidewater Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals.
| ABT | TDW | |
|---|---|---|
Market Cap | $187.95B | $4.54B |
Sector | Health | Utilities |
52-Week High | $136.62 | $91.20 |
52-Week Low | $82.57 | $47.29 |
Enterprise Value | $214.96B | $4.58B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Tidewater (TDW) trades at $90.20, up 0.64% today, with a bullish technical signal driven by moving averages and ADX. Recent Q2 2026 earnings beat estimates (EPS $0.43 vs. $0.32 expected, Zacks Investment Research, 2026-08-03), though quarterly EPS has missed expectations in three of the last four quarters. The company maintains strong profitability with an 18.34% net margin and robust cash flow from operations of $379.11 million in 2025.
Outlook is mixed: bullish technicals and institutional interest support upside, but earnings misses and a high RSI near overbought levels pose risks. Analyst consensus leans hold (57.7%), with valuation metrics like P/E of 18.5 suggesting fair pricing. Key risks include operational costs from Middle East conflicts and revenue volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
